J. F. Chan, S. Yuan, K. H. Kok, K. K. To, H. Chu et al., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster, Lancet (Lond. Engl.), vol.2020, pp.514-523

E. Dong, H. Du, and L. Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect. Dis, vol.20, pp.533-534, 2020.

N. Chen, M. Zhou, X. Dong, J. Qu, F. Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study, Lancet (Lond. Engl.), vol.2020, pp.507-513

D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu et al., Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in, vol.2020

G. Biondi-zoccai, G. Landoni, R. Carnevale, E. Cavarretta, S. Sciarretta et al., SARS-CoV-2 and COVID-19: Facing the pandemic together as citizens and cardiovascular practitioners. Minerva Cardioangiol, 2020.

Y. Han, H. Zeng, H. Jiang, Y. Yang, Z. Yuan et al., CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic, Circulation, 2020.

F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet

C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in, vol.2020, pp.497-506

S. Shi, M. Qin, B. Shen, Y. Cai, T. Liu et al., Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China, JAMA Cardiol, 2020.

N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang et al., A Novel Coronavirus from Patients with Pneumonia in China, New Engl. J. Med, vol.382, pp.727-733, 2019.

S. Su, G. Wong, W. Shi, J. Liu, A. C. Lai et al., Genetic Recombination, and Pathogenesis of Coronaviruses, vol.24, pp.490-502, 2016.

E. Driggin, M. V. Madhavan, B. Bikdeli, T. Chuich, J. Laracy et al., Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic, J. Am. Coll. Cardiol, 2020.

R. Lu, X. Zhao, J. Li, P. Niu, B. Yang et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding, Lancet (Lond. Engl.), vol.2020, pp.565-574

, Guidance for Risk Assessment and Public Health Management of Healthcare Personnel with Potential Exposure in a Healthcare Setting to Patients with Coronavirus Disease (COVID-19), p.25, 2020.

X. Y. Ge, J. L. Li, X. L. Yang, A. A. Chmura, G. Zhu et al., Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor, Nature, vol.503, pp.535-538, 2013.

P. Zhou, X. L. Yang, X. G. Wang, B. Hu, L. Zhang et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, vol.579, pp.270-273, 2020.

M. Hoffmann, H. Kleine-weber, S. Schroeder, N. Kruger, T. Herrler et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, vol.181, pp.271-280, 2020.

H. Zhang, J. M. Penninger, Y. Li, N. Zhong, and A. S. Slutsky, Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target

H. Xu, L. Zhong, J. Deng, J. Peng, H. Dan et al., High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa, Int. J. Oral Sci, vol.12, 2020.

B. Li, J. Yang, F. Zhao, L. Zhi, X. Wang et al., Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China, Clin. Res. Cardiol. Off. J. Ger. Card. Soc, 2020.

B. J. Coburn, B. G. Wagner, and S. Blower, Modeling influenza epidemics and pandemics: Insights into the future of swine flu (H1N1), BMC Med, vol.7, p.30, 2009.

A. Zumla, D. S. Hui, and S. Perlman, Middle East respiratory syndrome, Lancet (Lond. Engl.), vol.386, pp.995-1007, 2015.

S. Perlman, Another Decade, Another Coronavirus, N. Engl. J. Med, vol.2020, pp.760-762

K. Mizumoto, K. Kagaya, A. Zarebski, and G. Chowell, Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, vol.25, 2020.

L. Zou, F. Ruan, M. Huang, L. Liang, H. Huang et al., SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients, N. Engl. J. Med, vol.382, pp.1177-1179, 2020.

J. S. Peiris, C. M. Chu, V. C. Cheng, K. S. Chan, I. F. Hung et al., Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study, Lancet (Lond. Engl.), vol.361, pp.1767-1772, 2003.

W. J. Guan, Z. Y. Ni, Y. Hu, W. H. Liang, C. Q. Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N. Engl. J. Med, vol.382, pp.1708-1720, 2020.

S. A. Lauer, K. H. Grantz, Q. Bi, F. K. Jones, Q. Zheng et al., The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application, Ann. Intern. Med, 2020.

A. Giacomelli, L. Pezzati, F. Conti, D. Bernacchia, M. Siano et al., Self-reported olfactory and taste disorders in SARS-CoV-2 patients: A cross-sectional study, Clin. Infect. Dis, 2020.

J. A. Fried, K. Ramasubbu, R. Bhatt, V. K. Topkara, K. J. Clerkin et al., The Variety of Cardiovascular Presentations of COVID-19, Circulation, 2020.

S. Bangalore, A. Sharma, A. Slotwiner, L. Yatskar, R. Harari et al., ST-Segment Elevation in Patients with Covid-19-A Case Series, N. Engl. J. Med, 2020.

Z. Wu and J. M. Mcgoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention, vol.2020

G. Onder, G. Rezza, and S. Brusaferro, Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy, JAMA, 2020.

P. Goyal, J. J. Choi, L. C. Pinheiro, E. J. Schenck, R. Chen et al., Clinical Characteristics of Covid, vol.19, 2020.

C. M. Petrilli, S. A. Jones, J. Yang, H. Rajagopalan, L. F. O'donnell et al., Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease, vol.2020

N. Sattar, I. B. Mcinnes, and J. J. Mcmurray, Obesity a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms, Circulation, 2020.

M. A. Matthay, J. M. Aldrich, and J. E. Gotts, Treatment for severe acute respiratory distress syndrome from COVID-19, Lancet Respir. Med, 2020.

A. C. Kalil, Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics, JAMA, 2020.

K. Ramanathan, D. Antognini, A. Combes, M. Paden, B. Zakhary et al., Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases, Lancet Respir. Med, 2020.

C. M. Booth, L. M. Matukas, G. A. Tomlinson, A. R. Rachlis, D. B. Rose et al., Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area, JAMA, vol.289, pp.2801-2809, 2003.

A. Badawi and S. G. Ryoo, Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): A systematic review and meta-analysis, Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis, vol.49, pp.129-133, 2016.

T. Guo, Y. Fan, M. Chen, X. Wu, L. Zhang et al., Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease, 2019.

Q. Ruan, K. Yang, W. Wang, L. Jiang, and J. Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensiv. Care Med, 2020.

K. J. Clerkin, J. A. Fried, J. Raikhelkar, G. Sayer, J. M. Griffin et al., COVID-19) and Cardiovascular Disease, Coronavirus Disease, 2019.

C. M. Weyand and J. J. Goronzy, Aging of the Immune System. Mechanisms and Therapeutic Targets, Ann. Am. Thorac. Soc, vol.13, pp.422-428, 2016.

K. E. Dooley and R. E. Chaisson, Tuberculosis and diabetes mellitus: Convergence of two epidemics, Lancet Infect. Dis, vol.9, pp.737-746, 2009.

B. S. Rodrigues, C. David, J. Costa, J. J. Ferreira, F. J. Pinto et al., Influenza vaccination in patients with heart failure: A systematic review and meta-analysis of observational studies, Heart (Br. Card. Soc, vol.2020, pp.350-357

D. Caldeira, B. Rodrigues, C. David, J. Costa, F. J. Pinto et al., The association of influenza infection and vaccine with myocardial infarction: Systematic review and meta-analysis of self-controlled case series, Expert Rev. Vaccines, vol.18, pp.1211-1217, 2019.

M. Madjid and S. W. Casscells, Of birds and men: cardiologists' role in influenza pandemics, Lancet (Lond. Engl, vol.364, 1309.

M. Arentz, E. Yim, L. Klaff, S. Lokhandwala, F. X. Riedo et al., Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State, 2020.

R. M. Inciardi, L. Lupi, G. Zaccone, L. Italia, M. Raffo et al., Patient With Coronavirus Disease, 2019.

G. Y. Oudit, Z. Kassiri, C. Jiang, P. P. Liu, S. M. Poutanen et al., SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS, Eur. J. Clin. Investig, vol.39, pp.618-625, 2009.

T. Alhogbani, Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus, Ann. Saudi Med, vol.36, pp.78-80, 2016.

H. Hui, Y. Zhang, X. Yang, X. Wang, B. He et al., Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia, vol.2020

T. Y. Xiong, S. Redwood, B. Prendergast, and M. Chen, Coronaviruses and the cardiovascular system: Acute and long-term implications, Eur. Heart J, 2020.

G. Tavazzi, C. Pellegrini, M. Maurelli, M. Belliato, F. Sciutti et al., Myocardial localization of coronavirus in COVID-19 cardiogenic shock, Eur. J. Heart Fail, 2020.

P. Meyer, S. Degrauwe, C. V. Delden, and J. Ghadri, Typical takotsubo syndrome triggered by SARS-CoV-2 infection, Eur. Heart J, 2020.

H. Hu, F. Ma, X. Wei, and Y. Fang, Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin, Eur. Heart J, 2020.

J. H. Zeng, Y. X. Liu, J. Yuan, F. X. Wang, W. B. Wu et al., First Case of COVID-19 Infection with Fulminant Myocarditis Complication: Case Report and Insights, 2020.

J. C. Kwong, K. L. Schwartz, M. A. Campitelli, H. Chung, N. S. Crowcroft et al., Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection, N. Engl. J. Med, vol.378, pp.345-353, 2018.

K. Thygesen, J. S. Alpert, A. S. Jaffe, B. R. Chaitman, J. J. Bax et al., Fourth Universal Definition of Myocardial Infarction, vol.72, pp.2231-2264, 2018.

N. S. Hendren, M. H. Drazner, B. Bozkurt, T. Leslie, and J. Cooper, Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome, Circulation, 2020.

A. College and . Cardiology, Troponin and BNP Use in COVID-19, p.25, 2020.

I. C. Kim, J. Y. Kim, H. A. Kim, and S. Han, COVID-19-related myocarditis in a 21-year-old female patient, Eur. Heart J, 2020.

, Clinical Management of Severe Acute Respiratory Infection When COVID-19 is Suspected, p.25, 2020.

M. S. Alshahrani, A. Sindi, F. Alshamsi, A. Al-omari, M. El-tahan et al., Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus, Ann. Intensiv. Care, vol.8, issue.3, 2018.

M. Madjid, A. T. Connolly, Y. Nabutovsky, P. Safavi-naeini, M. Razavi et al., Effect of High Influenza Activity on Risk of Ventricular Arrhythmias Requiring Therapy in Patients With Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators, Am. J. Cardiol, vol.124, pp.44-50, 2019.

C. M. Yu, R. S. Wong, E. B. Wu, S. L. Kong, J. Wong et al., Cardiovascular complications of severe acute respiratory syndrome, Postgrad. Med. J, vol.82, pp.140-144, 2006.

N. Tang, D. Li, X. Wang, and Z. Sun, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J. Thromb. Haemost, vol.2020, pp.844-847

J. Thachil, N. Tang, S. Gando, A. Falanga, M. Cattaneo et al., ISTH interim guidance on recognition and management of coagulopathy in COVID-19, J. Thromb. Haemost, 2020.

P. Y. Chong, P. Chui, A. E. Ling, T. J. Franks, D. Y. Tai et al., Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: Challenges in determining a SARS diagnosis, Arch. Pathol. Lab. Med, vol.128, pp.195-204, 2004.

L. Zhang, F. Zhu, L. Xie, C. Wang, J. Wang et al., Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann. Oncol, 2020.

G. B. Danzi, M. Loffi, G. Galeazzi, and E. Gherbesi, Acute pulmonary embolism and COVID-19 pneumonia: A random association?, Eur. Heart J, 2020.

Y. Xie, X. Wang, P. Yang, and S. Zhang, COVID-19 Complicated by Acute Pulmonary Embolism, Radiol. Cardiothorac. Imaging, vol.2020, 200067.

T. Ai, Z. Yang, H. Hou, C. Zhan, C. Chen et al., Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases

Y. Yang, M. Yang, C. Shen, F. Wang, J. Yuan et al., Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections, vol.2020

B. Alosaimi, M. E. Hamed, A. Naeem, A. A. Alsharef, S. Y. Alqahtani et al., MERS-CoV infection is associated with downregulation of genes encoding Th1 and Th2 cytokines/chemokines and elevated inflammatory innate immune response in the lower respiratory tract, Cytokine, vol.126, 2020.

L. Lin, L. Lu, W. Cao, and T. Li, Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia, Emerg. Microbes Infect, vol.2020, pp.727-732

R. Escher, N. Breakey, and B. Lämmle, Severe COVID-19 infection associated with endothelial activation, Thromb. Res, 2020.

C. Sardu, J. Gambardella, M. B. Morelli, X. Wang, R. Marfella et al., Is COVID-19 an Endothelial Disease? Clinical and Basic Evidence, 2020.

Z. Varga, A. J. Flammer, P. Steiger, M. Haberecker, R. Andermatt et al., Endothelial cell infection and endotheliitis in COVID-19, Lancet (Lond. Engl.), 2020.

A. R. Santos, P. Freitas, J. Ferreira, A. Oliveira, M. Goncalves et al., Risk stratification in normotensive acute pulmonary embolism patients: Focus on the intermediate-high risk subgroup, Eur. Heart J. Acute Cardiovasc. Care, 2019.

M. Kosuge, T. Ebina, K. Hibi, K. Tsukahara, N. Iwahashi et al., Differences in negative T waves between acute pulmonary embolism and acute coronary syndrome, Circ. J. Off. J. Jpn. Circ. Soc, vol.78, pp.483-489, 2014.

I. Hamming, W. Timens, M. L. Bulthuis, A. T. Lely, G. Navis et al., Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J. Pathol, vol.203, pp.631-637, 2004.

Y. Imai, K. Kuba, S. Rao, Y. Huan, F. Guo et al., Angiotensin-converting enzyme 2 protects from severe acute lung failure, Nature, vol.436, pp.112-116, 2005.

A. B. Patel and A. Verma, COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? JAMA 2020

G. M. Kuster, O. Pfister, T. Burkard, Q. Zhou, R. Twerenbold et al., Should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur. Heart J. 2020

Z. Kassiri, J. Zhong, D. Guo, R. Basu, X. Wang et al., Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction, Circ. Heart Fail, vol.2, pp.446-455, 2009.

M. Vaduganathan, O. Vardeny, T. Michel, J. J. Mcmurray, M. A. Pfeffer et al., Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19, N. Engl. J. Med, 2020.

L. Fang, G. Karakiulakis, and M. Roth, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Respir. Med, 2020.

Y. Y. Zheng, Y. T. Ma, J. Y. Zhang, and X. Xie, COVID-19 and the cardiovascular system, Nat. Rev. Cardiol, vol.2020, pp.259-260

C. M. Ferrario, J. Jessup, M. C. Chappell, D. B. Averill, K. B. Brosnihan et al., Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation, vol.111, pp.2605-2610, 2005.

Y. Ishiyama, P. E. Gallagher, D. B. Averill, E. A. Tallant, K. B. Brosnihan et al., Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors, Hypertension, vol.43, pp.970-976, 1979.

M. Furuhashi, N. Moniwa, T. Mita, T. Fuseya, S. Ishimura et al., Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker, Am. J. Hypertens, vol.28, pp.15-21, 2015.

J. Ramchand, S. K. Patel, P. M. Srivastava, O. Farouque, and L. M. Burrell, Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease, PLoS ONE, vol.13, 2018.

S. Epelman, K. Shrestha, R. W. Troughton, G. S. Francis, S. Sen et al., Soluble angiotensin-converting enzyme 2 in human heart failure: Relation with myocardial function and clinical outcomes, J. Card. Fail, vol.15, pp.565-571, 2009.

P. Zhang, L. Zhu, J. Cai, F. Lei, J. Qin et al., Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19, Circ. Res, 2020.

. American-college-of-cardiology, . Hfsa/acc/aha, and . Statement, Addresses Concerns Re: Using RAAS Antagonists in COVID-19, p.25, 2020.

E. Society and . Cardiology, Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers, p.25, 2020.

, COVID-19 and Concerns Regarding Use of ACEi/ARB/ARNi Medications for Heart Failure or Hypertension, Canadian Cardiovascular Society, p.25, 2020.

M. Madjid, P. Safavi-naeini, S. D. Solomon, and O. Vardeny, Potential Effects of Coronaviruses on the Cardiovascular System: A Review, JAMA Cardiol, 2020.

B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang et al., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N. Engl. J. Med, vol.382, pp.1787-1799, 2020.

M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, vol.30, pp.269-271, 2020.

P. Gautret, J. C. Lagier, P. Parola, V. T. Hoang, L. Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents, 2020.
URL : https://hal.archives-ouvertes.fr/hal-02525126

H. Yogasundaram, W. Hung, I. D. Paterson, C. Sergi, and G. Y. Oudit, Chloroquine-induced cardiomyopathy: A reversible cause of heart failure, ESC Heart Fail, vol.5, pp.372-375, 2018.

E. Tonnesmann, R. Kandolf, and T. Lewalter, Chloroquine cardiomyopathy-A review of the literature, Immunopharmacol. Immunotoxicol, vol.35, pp.434-442, 2013.

A. College and . Cardiology, Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment for COVID-19, p.25, 2020.

V. F. Corrales-medina, K. N. Alvarez, L. A. Weissfeld, D. C. Angus, J. A. Chirinos et al., Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease, JAMA, vol.313, pp.264-274, 2015.